Drug Profile
Research programme: infectious disease vaccines - PaxVax
Alternative Names: Dengue vaccine - PaxVax; Human papillomavirus infections vaccine - PaxVax; Influenza virus infections vaccine - PaxVax; Malaria vaccine - PaxVax; Poliomyelitis vaccine - PaxVax; Rabies vaccine - PaxVax; Shigella vaccine - PaxVax; Tuberculosis vaccine -PaxVax; Zika virus vaccine - PaxVaxLatest Information Update: 28 Apr 2020
Price :
$50
*
At a glance
- Originator PaxVax
- Class Bacterial vaccines; DNA vaccines; Parasitic vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Dengue; Human papillomavirus infections; Influenza virus infections; Malaria; Poliomyelitis; Rabies; Shigella infections; Tuberculosis; Zika virus infection
Most Recent Events
- 28 Apr 2020 No recent reports of development identified for research development in Zika-virus-infection(Prevention) in USA
- 04 Oct 2018 PaxVax has been acquired by Emergent BioSolutions
- 28 Aug 2018 No recent reports of development identified for research development in Dengue(Prevention) in USA (PO)